Standout Papers

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma 2007 2026 2013 2019 2.8k
  1. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma (2007)
    Gary R. Hudes, Michael A. Carducci et al. New England Journal of Medicine

Immediate Impact

6 by Nobel laureates 24 from Science/Nature 75 standout
Sub-graph 1 of 21

Citing Papers

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
2022 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
18 intermediate papers

Works of Janice Dutcher being referenced

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)
2015
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Janice Dutcher 2516 1041 98 2351 1363 13 3.6k
Vladimir Lesovoy 2294 815 25 2178 1295 8 3.4k
Zoran Kovačević 2039 714 17 1991 1123 29 2.9k
Norbert Hollaender 2459 1029 34 2365 1270 29 3.9k
Gladys Urbanowitz 2175 1980 21 1904 981 12 4.1k
Debasish Roychowdhury 2053 1041 99 1453 858 19 3.0k
Erhan Gökmen 2198 1013 18 2049 1259 54 3.3k
N. Moore 2553 1921 111 1711 1208 27 3.9k
E Solska 3889 1827 222 3319 2036 6 5.5k
David McDermott 2313 798 20 2184 1269 3 3.1k
Stephanie Lustgarten 2055 781 36 2039 1115 60 3.5k

All Works

Loading papers...

Rankless by CCL
2026